Meta-Analysis Compares Efficacy of Three Key Drugs for Fatty Liver Disease
Background
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as NAFLD, is a global health crisis affecting over 25% of the adult population, often progressing to more severe forms like Metabolic Dysfunction-Associated Steatohepatitis (MASH) and cirrhosis. Despite its prevalence, effective pharmacological treatments remain limited, leading to significant morbidity and mortality. This meta-analysis addresses the critical need to systematically evaluate and compare the efficacy of emerging therapeutic agents—tirzepatide, lanifibranor, and resmetirom—for MASLD based on robust clinical evidence.
Results
The meta-analysis revealed that all three agents demonstrated significant efficacy in improving MASLD outcomes compared to placebo. Specifically, tirzepatide, a dual GLP-1/GIP receptor agonist, showed a remarkable 60-70% MASLD resolution rate without worsening fibrosis, alongside an average 10-15% body weight reduction. Lanifibranor, a pan-PPAR agonist, achieved 40-50% MASLD resolution and a 25-30% improvement in fibrosis stage. Resmetirom, a selective thyroid hormone receptor-beta (THR-β) agonist, consistently led to 70-80% MASLD resolution and a 20-25% fibrosis improvement. The pooled analysis indicated that all three drugs significantly reduced liver fat content by an average of 30-50% from baseline, with resmetirom showing a slightly higher magnitude of reduction in some subgroups. While direct head-to-head comparisons were limited, the data suggest distinct mechanistic benefits, with tirzepatide excelling in metabolic control and weight loss, and lanifibranor and resmetirom demonstrating strong direct anti-fibrotic and steatosis-reducing effects.
Why It Matters
This meta-analysis provides crucial insights into the comparative efficacy of three leading investigational therapies for MASLD, offering valuable guidance for clinical development and future treatment strategies. The consistent and significant improvements across multiple MASLD endpoints highlight the potential for these drugs to transform patient care. These findings strongly support the continued development of tirzepatide, lanifibranor, and resmetirom, potentially leading to their clinical approval and widespread use as the first effective pharmacological treatments for MASLD and MASH. Future research should focus on head-to-head clinical trials and real-world evidence to further refine treatment algorithms and identify optimal patient populations for each agent.